Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Cash (2020 - 2025)

Historic Change in Cash for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $24.8 million.

  • Lyell Immunopharma's Change in Cash rose 17478.57% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 11321.77%. This contributed to the annual value of -$38.6 million for FY2024, which is 27488.35% down from last year.
  • Per Lyell Immunopharma's latest filing, its Change in Cash stood at $24.8 million for Q3 2025, which was up 17478.57% from -$21.6 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Change in Cash ranged from a high of $320.1 million in Q2 2021 and a low of -$170.9 million during Q3 2021
  • Over the past 5 years, Lyell Immunopharma's median Change in Cash value was -$14.1 million (recorded in 2023), while the average stood at -$826947.4.
  • Over the last 5 years, Lyell Immunopharma's Change in Cash had its largest YoY gain of 78189.48% in 2023, and its largest YoY loss of 204044.73% in 2023.
  • Over the past 5 years, Lyell Immunopharma's Change in Cash (Quarter) stood at -$99.7 million in 2021, then skyrocketed by 107.27% to $7.2 million in 2022, then plummeted by 2040.45% to -$140.6 million in 2023, then soared by 104.77% to $6.7 million in 2024, then soared by 269.73% to $24.8 million in 2025.
  • Its last three reported values are $24.8 million in Q3 2025, -$21.6 million for Q2 2025, and $14.7 million during Q1 2025.